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of Women’s Health instruments. Both aggregate analyses 
and country-specific analyses are planned for total costs per 
patient. Costs are broken down into cost drivers and into the 
various payers that incur costs.  Conclusions: The cost esti-
mates provided by the EndoCost cost-of-illness analysis may 
be used to justify the prioritisation of future research in en-
dometriosis.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Endometriosis is defined as the presence of endome-
trial-like tissue outside the uterus, which induces a chron-
ic, inflammatory reaction. The condition is predomi-
nantly found in women of reproductive age, from all eth-
nic and social groups. The associated symptoms can 
impact on general physical, mental and social well-being 
 [1] . Endometriosis is associated with: severe dysmenor-
rhoea; deep dyspareunia; chronic pelvic pain; ovulation 
pain; cyclical or peri-menstrual symptoms (e.g. bowel or 
bladder associated) with or without abnormal bleeding; 
infertility, and chronic fatigue. Some affected women, 
however, remain asymptomatic.
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 Abstract 
 Aims: The EndoCost study aims to calculate the costs of 
 endometriosis from a societal perspective.  Methods: This 
multicentre, prevalence-based cost-of-illness analysis ag-
gregates data on endometriosis costs and quality of life from 
a prospective hospital questionnaire and from both retro-
spective and prospective patient questionnaires. The Endo-
Cost study comprises 12 representative tertiary care centres 
involved in the care of women with endometriosis in 10 
countries. The sample includes patients with a laparoscopic 
and/or histological diagnosis of endometriosis and with at 
least 1 patient contact related to endometriosis during 2008. 
The EndoCost study measures direct healthcare costs (e.g. 
costs of medication, physician visits), direct non-healthcare 
costs (e.g. transportation costs), and indirect costs of produc-
tivity loss. Cost questions are developed specifically for the 
purpose of the EndoCost study. Quality of life is measured 
using the EuroQol-5D and relevant parts of the Global Study 
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 The estimated prevalence of endometriosis is 10% 
among women of reproductive age, rising to 30–50% in 
patients with infertility and/or pain  [2] . Endometriosis is 
a complicated disease that often goes undiagnosed for 
years  [3] . Medical or surgical treatment aims to reduce 
symptoms, and to remove or diminish disease. Medical 
treatment is based on hormonal suppression and appears 
to be effective in treating pain associated with endome-
triosis, though the side effects and cost profiles differ 
 between medicines. Surgical treatment is effective in 
treating endometriosis-associated pain, and most likely 
also in treating endometriosis-associated subfertility  [1] . 
However, recurrence of endometriosis after surgery and 
after cessation of medical therapies occurs regularly.
 The endometriosis-associated costs to society are con-
siderable but yet poorly identified, as are the costs to the 
individual when disease symptoms interfere with day-to-
day life at work or at home  [3] . Diagnostic and surgical 
procedures, medicines, fertility treatments and involve-
ment of healthcare professionals all factor in when a 
woman presents with and/or is treated for symptoms sug-
gestive of endometriosis. Societal costs not only consist of 
costs of appropriate treatment of diagnosed endometrio-
sis, but also include costs of possible under-treatment as 
a result of delayed diagnosis and ‘hit and miss’ treatments 
 [4–7] .
 In a context of spiralling healthcare costs and limited 
resources, public policy makers and healthcare payers are 
concerned about the costs of endometriosis. Cost esti-
mates can underline the importance of endometriosis to 
society when considered alongside its impact on morbid-
ity and mortality and when compared with the econom-
ic burden of other diseases. Furthermore, cost studies 
may allow the identification of the drivers of diagnosis 
and treatment costs. Finally, cost data can be fed into eco-
nomic evaluations, so that decision makers can ascertain 
the cost-effectiveness of various approaches to diagnos-
ing and treating endometriosis by examining their effec-
tiveness in relation to their costs. A cost-of-illness study 
is a formal way of providing such cost estimates.
 A disease, which has such a profound effect on society, 
needs to be recognised and dealt with by society, and pub-
lic health initiatives need to be undertaken to generate 
awareness of the high prevalence and burden of endome-
triosis at all levels of society  [5, 7] . Action for increased 
awareness and investment in research has so far resulted 
in unprecedented recognition of endometriosis by the 
European Parliament in 2005 and 2006  [7] . Inspired by 
this recognition, the Italian Senate has recognised endo-
metriosis as a social disease and has produced a 5-year 
plan to improve treatment of endometriosis at a national 
level  [7] . But to get further recognition, in more than one 
country, the calculation of endometriosis costs will be in-
strumental to trigger increased awareness of endometrio-
sis among those who determine health policy and grant 
research funding.
 Three review papers have been published in recent 
years underlining the lack of research on costs of endo-
metriosis and that identifying several avenues for future 
research which the EndoCost study seeks to address  [6, 8, 
9] . To close the gaps identified in these papers in investi-
gating the costs of endometriosis, the aim of the Endo-
Cost study is to calculate the costs of endometriosis from 
a societal perspective. For this purpose, a prospective, 
prevalence-based, multicentre cost-of-illness analysis is 
set up to collect cost data using a bottom-up approach. 
This approach is combined with an assessment of endo-
metriosis-related quality of life in participating patients. 
The cost estimates provided by this cost-of-illness analy-
sis may be used to justify the prioritisation of future re-
search in endometriosis.
 The EndoCost Consortium decided to submit this 
study protocol for publication in order to raise awareness 
of endometriosis among policy makers and to encourage 
other researchers to carry out cost studies of endometrio-
sis. The publication of a study protocol is seen by the Con-
sortium as a natural step in the process of designing, con-
ducting and reporting on a study. This study protocol 
presents detailed information about the different steps in-
volved in designing the EndoCost study and may thereby 
inform the design of future cost studies of endometriosis.
 Materials and Methods 
 The methodology of the EndoCost study is reported using the 
STROBE statement for reporting observational studies  [10] .
 Study Design 
 The multicentre cost-of-illness analysis involves the identifi-
cation, quantification, and valuation of resources related to endo-
metriosis  [11] from an international perspective. This prevalence-
based study measures costs attributable to a group of women suf-
fering from endometriosis during a 2-month period. A bottom-up 
approach aggregates data derived from three sources: a prospec-
tive hospital questionnaire measures hospital costs related to en-
dometriosis, and two patient questionnaires identify costs and 
quality of life related to endometriosis prospectively and retro-
spectively.
 Ethical approval for the EndoCost study was obtained from 
the ethical committee associated with each participating centre. 
Women are required to sign an informed consent form in order 
to participate in the EndoCost study.
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 Setting 
 The EndoCost study involved the establishment of a research 
network known as the EndoCost Consortium. In 2007, a letter of 
invitation was sent to all members of the Special Interest Group 
for  Endometriosis  and  Endometrium  of  the   European   Society 
of Human Reproduction and Embryology (ESHRE) to join the 
EndoCost Consortium. The conditions to join the Consortium 
were: motivation to spend time on this study; good knowledge of 
written and spoken English; ability to get information from do-
mestic health authorities, and willingness to attend a number of 
Consortium meetings. Twelve centres in ten countries signed up 
to be part of the EndoCost Consortium.
 The EndoCost study wishes to provide cost estimates of endo-
metriosis from multiple countries that differ in terms of the or-
ganisation and financing of their healthcare system, including 
Belgium, Denmark, France, Germany, Hungary, Italy, The Neth-
erlands, Switzerland, the United Kingdom and the United States. 
Aggregate as well as country-specific cost estimates are to be cal-
culated. Each participating country includes one or more repre-
sentative of tertiary care centres involved in the care of gynaeco-
logical patients. Recognition of a representative centre is based on 
the recognition of this centre as a referral centre for patients with 
endometriosis-associated symptoms within and outside a coun-
try. For each country, a team of one or more gynaecologists and 
one health economic expert with a major interest in the epide-
miologic, public health, and cost aspects of endometriosis par-
ticipate in the EndoCost Consortium.
 Participants 
 The study population includes women with a laparoscopic and/
or histological diagnosis of endometriosis and with at least one 
patient contact between January 1 and December 31, 2008, related 
to endometriosis-associated symptoms (dysmenorrhoea; deep 
dyspareunia; chronic pelvic pain; ovulation pain; cyclical or peri-
menstrual symptoms, e.g. bowel or bladder associated, with or 
without abnormal bleeding; infertility, and chronic fatigue). The 
diagnosis of endometriosis was not necessarily made in this time 
period and patients who had been diagnosed earlier were included 
as long as they had one centre contact due to endometriosis during 
the calendar year of 2008. It was not required that endometriosis 
diagnosed by laparoscopy was confirmed by biopsy with positive 
histology. Patients with endometriosis proven after histological/
cytological analysis of an ovarian cyst (i.e. during egg aspiration 
for in vitro fertilisation) or of a deeply invasive rectovaginal nodule 
(i.e. biopsy of vaginal endometriosis) could also be included.
 The study included neither patients with suspected endome-
triosis, as suggested by imaging techniques like gynaecological 
ultrasound or magnetic resonance imaging, nor patients with a 
history of endometriosis who came to the hospital for a clinical 
problem unrelated to endometriosis (e.g. prenatal care, caesarean 
section, delivery or postnatal care, pelvic floor problems). Patients 
who had symptoms but did not have a confirmed diagnosis of en-
dometriosis were excluded. The study did not include a control 
population of women without endometriosis.
 Variables 
 The EndoCost study measures direct healthcare costs (e.g. 
costs of medication, physician visits and hospitalisation) as well 
as direct non-healthcare costs (e.g. transportation costs, child 
care costs, etc.). Indirect non-healthcare costs relating to reduced 
productivity as a result of endometriosis and its treatment are in-
cluded. These costs not only consist of the reduced productivity 
of the woman, but also of the loss of productivity of family/friends 
who take time off work to care for the woman. Other indirect non-
healthcare costs such as the costs of support with household ac-
tivities are documented.
 Endometriosis costs are calculated from the societal perspec-
tive. This includes costs incurred by the healthcare payer (i.e. in-
surance funds or National Health Service), the patient/family (i.e. 
co-payment or full payment for medicines and/or care) and by the 
society at large (i.e. costs of reduced productivity).
 The EndoCost Consortium is aware of the complexity in-
volved in estimating the economic burden of endometriosis and, 
thus, the EndoCost study purports to attain a truthful and com-
prehensive representation of the costs of endometriosis. As an ex-
ample,  table 1 identifies the major cost items which need to be 
considered when calculating the costs of endometriosis from a 
societal perspective.
 Data Sources/Measurement 
 Relevant questions regarding direct and indirect costs of en-
dometriosis were compiled into one retrospective and one pro-
spective patient questionnaire, and a prospective hospital ques-
tionnaire. In general, cost questions were developed specifically 
for the purpose of the EndoCost study by the participating health 
economists and gynaecologists, except for the Work Productivity 
and Activity Impairment Questionnaire  [12] . Quality of life was 
measured using the EuroQol-5D  [13] and relevant parts of the 
Global Study of Women’s Health (GSWH) instruments  [14] . Cop-
ies of the questionnaires are available from the corresponding au-
thor on request.
 The prospective hospital questionnaire measured the start 
and end dates of patient hospitalisations; the number of monitor-
ing tests; the trade name, daily dosage, and number of days of 
patient medication; the number and type of outpatient physician 
consultations; the number and type of surgical procedures and/
or infertility treatments; the number and type of other therapies 
from October 5 until November 30, 2009.
 In the prospective patient questionnaire, questions related to 
the number and type of physician consultations; the trade name, 
daily dosage, and number of days of patient medication; the num-
ber of monitoring tests; the start and end dates of patient hospi-
talisations; the number and type of other therapies; the dates and 
number of hours of additional support with household activities; 
the dates, type and number of hours of informal care, and loss of 
productivity from October 5 until November 30, 2009. The pro-
ductivity loss was measured using the Work Productivity and Ac-
tivity Impairment Questionnaire  [12] . This generic instrument 
considered the time lost from work (‘absenteeism’) as well as re-
duced productivity at work (‘presenteeism’). To register the evolu-
tion of health-related quality of life over time, the EuroQol-5D 
 [13] instrument was filled in by patients on October 2, November 
2 and November 30, 2009. The EuroQol-5D is a generic instru-
ment which contains 5 dimensions of health-related quality of 
life: mobility, self-care, daily activities, pain/discomfort and de-
pression/anxiety. Each dimension can be rated at three levels: no 
problems, some problems and major problems. The five dimen-
sions can be summed into a health state.
 The retrospective patient questionnaire enquired about the 
woman’s demographic characteristics and medical history (e.g. 
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age, weight, educational level, marital status, ethnic origin, year 
and type of first symptoms, year of endometriosis diagnosis); the 
number and type of lifetime surgical procedures; the number of 
lifetime cycles of infertility treatments; as well as the trade name 
and number of months of hormonal treatment; the number and 
type of physician consultations; the trade name, daily dosage, and 
number of days of patient medication; the number of monitoring 
tests; the start and end dates of patient hospitalisations; the num-
ber and type of other therapies; the dates and number of hours of 
support with household activities; the dates, type and number of 
hours of informal care; and productivity loss from August 6 until 
October 1, 2009. The impact of endometriosis on quality of life 
was measured by the GSWH instrument as this allowed compar-
ison with this prospective study of naive patients  [14] . The vali-
dated GSWH instrument is based on the Short Form-36 (SF-36), 
a generic 8-scale profile of physical and mental health  [15] , and 
the Endometriosis Health Profile-30 (EHP 30), a disease-specific 
instrument that measures health-related quality of life associated 
with endometriosis  [16] .
 The questionnaires elicited data about the volume of resource 
use associated with endometriosis. To value resource use, price 
data were collected using the following principles.
 (1) Prices reflected unit costs based on actual resource use as 
much as possible. In the absence of unit cost data, charges based 
on official list prices were used.
 (2) Prices reflected the contribution of the healthcare payer 
and the patient co-payment.
 (3) Prices reflected generic costs. For example, the EndoCost 
study wished to collect the generic cost of an ultrasound examina-
tion, but not necessarily patient X’s ultrasound on a specific date. 
Each participating country’s health economist was responsible for 
collecting the price data using a standardised form in collabora-
tion with the gynaecologist.
 Utility values were calculated for the health states identified 
by the EuroQol-5D using a national health utility index. The util-
ity values are used to compute quality-adjusted life years (QALYs), 
if combined with estimates of the time period for which a par-
ticular health state lasts. The QALY is an outcome measure that 
accounts for the quantity and quality of life, and that allows com-
parison of outcomes between diseases.
 The questionnaires were piloted and reviewed for face and 
content validity by the members of the EndoCost Consortium and 
by 6 patients at the Katholieke Universiteit Leuven. Respondents 
discussed the relevance of questions, commented on their word-
ing and interpretation, and checked whether all potential answers 
were included. As a result, medical terms were clarified, ambigu-
ous questions were reformulated for greater clarity, and answer 
categories were added where appropriate.
 Study Size 
 As is usual practice in cost-of-illness analyses, this study is 
designed to measure costs rather than test a specific hypothesis 
about costs and, therefore, no sample size calculations were con-
ducted. Each referral centre identified eligible patients and 3,216 
women were invited on August 31, 2009, to participate in the 
study and 1,450 women (response rate of 45%) provided informed 
consent in time to be mailed the questionnaires on September 24, 
2009. This sample size is larger than previous studies on the costs 
of endometriosis that tended to include only a few hundred pa-
tients  [6] . Data collection has now been completed and data anal-
ysis has just been started. Results of the EndoCost study will be 
reported over the course of the next years.
 Statistical Methods 
 Data collection and input into the central database are carried 
out in each participating centre. Missing values are to be expect-
ed, but are minimised primarily by using several categories such 
as ‘not applicable’ and ‘not known’. Each centre may contact pa-
tients to supplement answers for missing values and standard sta-
tistical techniques are utilised to deal with missing data. Overall 
quality assurance of data entry and data analysis is carried out by 
the coordinating health economist (S.S.) at the University Hospi-
tal Leuven, the coordinating centre of the EndoCost study.
 Statistical analyses are primarily of a descriptive nature. A de-
scriptive analysis is carried out on the demographic characteris-
tics of patients. Characteristics are reported as relative frequen-
cies for categorical data, and as mean ( 8 standard deviation) or 
median (and quartiles) for continuous data depending on the nor-
mality of the data.
 Prospective and retrospective analyses are carried out sepa-
rately. An aggregate analysis is planned for the volume of resource 
use and total costs. Costs per patient are computed by multiplying 
resource use by unit costs. The following cost measures are calcu-
lated: costs per patient, annual costs per patient, and costs per 
centre.
 Costs per patient are computed and summarised using the fol-
lowing descriptive statistics: mean, standard deviation, median, 
5th and 95th percentiles. Since costs do not usually follow a nor-
mal distribution, a robust confidence interval of the mean is also 
calculated. This interval is calculated by means of the bootstrap-
ping method, a technique which does not require the assumption 
of normality  [17] .
 Total costs are broken down into the major cost drivers (e.g. 
hospitalisation, medicines, productivity loss, etc.) and into the 
major payers that incur those costs (insurance fund/National 
Health Service and patients). Country-specific analyses are con-
ducted for total costs. Extrapolation from the sample to the whole 
country is not a goal of the study, while extrapolation from the 
sample to the annual cost per centre is possible.
 Costs are expressed in euros. For those countries that do not 
have the euro, costs are converted into euros using purchasing 
power parity exchange rates, i.e. market exchange rates adjusted 
for differences in purchasing power between countries  [18] . The 
price year is 2009.
 Discussion 
 The EndoCost study purports to calculate the level of 
endometriosis costs, elicit the most important drivers of 
endometriosis costs, and identify factors that influence 
the level of endometriosis costs. Cost estimates may be 
used to raise awareness of endometriosis with policy 
makers, healthcare professionals, and research institu-
tions in order to underline that early diagnosis and treat-
ment, not ‘hit and miss treatments’, may reduce costs on 
a  societal  and  personal level. The hypothesis is that 
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 results from this study are fundamental in justifying 
 significant investment in endometriosis research to un-
derstand disease mechanisms (pathogenesis and the 
path ophysiology of endometriosis-related pain and/or 
infertility) which may lead to improved diagnostics and 
therapeutics, which may in turn reduce the socio-eco-
nomic impact of the disease.
 To the best of the authors’ knowledge, the EndoCost 
study is the first international, multicentre cost-of-illness 
study assessing the costs of endometriosis from a societal 
perspective. Ideally, the true cost of a disease is measured 
by the additional burden imposed by that disease on so-
ciety. This additional burden takes the form of increased 
resource utilisation by endometriosis patients, which ex-
ceeds the use of resources by the general population  [19] . 
For this purpose, a case-control study design can be used 
to compare total costs of endometriosis patients with 
costs of an equivalent standardised population with a 
view to calculating the additional costs that can be attrib-
uted to endometriosis. Due to practical and resource con-
straints, the EndoCost study did not include a control 
population of patients without endometriosis. Instead, 
the EndoCost questionnaires enquired about the costs 
specifically related to endometriosis. However, it will be 
possible to compare the results of this study with nation-
al statistics regarding age- and gender-corrected ‘per cap-
ita’ spending on healthcare services.
 Each participating country includes one or more rep-
resentative tertiary care centres involved in women’s 
health. These centres typically have women with endo-
metriosis referred to them and, therefore, our cost esti-
mates can be expected to reflect ideal practice, but may 
be different from the costs of endometriosis observed in 
other centres, since more complex cases of endometriosis 
are normally referred to a tertiary care centre.
 The two patient questionnaires identify costs and 
quality of life related to endometriosis prospectively and 
retrospectively. The retrospective assessment is impor-
tant in order to get optimal data out of this study, al-
though  the  investigators fully recognise the limitations 
of this method of data collection due to potential recall 
bias. Therefore, the retrospective questionnaire uses a re-
call period of only 2 months. This is in line with previous 
research recommendations when estimating costs due to 
illness  [20] .
 The EndoCost study takes a prevalence-based ap-
proach, measuring endometriosis costs within a given 
time interval, rather than an incidence-based approach, 
quantifying lifetime costs of endometriosis from onset to 
death. An incidence-based approach would be better 
suited to take into account the recurrence of endometrio-
sis and its associated costs. However, an international, 
multicentre cost analysis based on an incidence-based 
approach was not feasible due to practical and resource 
constraints.
 This international study provides evidence of the costs 
of endometriosis in multiple countries. The reader should 
note that differences in the organisation and financing of 
healthcare systems are likely to influence reported cost 
estimates. Therefore, country-specific as well as aggre-
gate cost estimates are to be calculated and country- 
specific estimates can be used to inform national health 
policy.
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